RXi Pharmaceuticals Corp. (RXII)

2.58
NASDAQ : Health Technology
Prev Close 2.37
Day Low/High 2.22 / 2.84
52 Wk Low/High 1.90 / 7.70
Avg Volume 391.40K
Exchange NASDAQ
Shares Outstanding 4.26M
Market Cap 10.04M
EPS -5.50
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.

Focused on Speculative Trading: RXII, BB, CASA

Focused on Speculative Trading: RXII, BB, CASA

We have this drifting action and uncorrelated action between stocks and the indices.

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

My biggest concern about the market continues to be a paucity of perky picks.

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

-- Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials

RXi Pharmaceuticals Announces Positive Results From Phase 2 Trial With RXI-109 For Dermal Scarring

RXi Pharmaceuticals Announces Positive Results From Phase 2 Trial With RXI-109 For Dermal Scarring

- RXI-109 is a self-delivering RNAi (sd-rxRNA) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and plays a key role in tissue regeneration and repair.

Medigene Collaborates With RXi Pharmaceuticals To Further Sharpen Its Therapeutic T Cells

Medigene Collaborates With RXi Pharmaceuticals To Further Sharpen Its Therapeutic T Cells

- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharmaceuticals will be explored preclinically

RXi Pharmaceuticals And The Center For Cancer Immune Therapy At Herlev Hospital Announce Research Collaboration

RXi Pharmaceuticals And The Center For Cancer Immune Therapy At Herlev Hospital Announce Research Collaboration

The Center for Cancer Immune Therapy at Herlev Hospital, University of Copenhagen, is a leading European cancer center that received a Global Excellence Award in 2013 from the Capital Region of Denmark

RXi Pharmaceuticals Announces Positive Results With RXI-231 In Consumer Testing Program

RXi Pharmaceuticals Announces Positive Results With RXI-231 In Consumer Testing Program

RXI-231 is a cosmetic ingredient in a proprietary gel formulation designed to aid in the reduction of pigmentation to improve skin appearance

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

TheStreet Quant Rating: E+ (Sell)